Drug
Daclatasvir clinical trials
Also written BMS-790052, Daklinza and DCV.
- studies test it
- 92
- open now
- 0
- in phase 3
- 35
- first study started
- 2007
How studies write it
Studies that test it under each name
Studies by the year they started
92 studies that test it; most in 2014 (19)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 8 |
| 2013 | 7 |
| 2014 | 19 |
| 2015 | 16 |
| 2016 | 9 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 19
- Phase 2
- 34
- Phase 3
- 35
- Phase 4
- 6
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 60 · Other 32
Bristol-Myers Squibb (46) · ANRS, Emerging Infectious Diseases (3) · Tehran University of Medical Sciences (3) · Humanity and Health Research Centre (3) · Assiut University (3) · Genuine Research Center, Egypt (3) · Janssen Research & Development, LLC (2) · Radboud University Medical Center (2)
Often tested with
Tested in the same studies.
Sofosbuvir (28) · Asunaprevir (23) · Ribavirin (20) · Simeprevir (9) · Beclabuvir (9) · Peginterferon alfa-2a (8) · Peginterferon lambda-1a (5) · Ritonavir (4)
Studies
Open first, then newest update. How each study uses daclatasvir is read from its arms, and is right about nine times in ten.
Testing it · 92
- Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)CompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02107365Written as Daclatasvir
- Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCCCompletedPhase 3National Hepatology & Tropical Medicine Research InstituteNCT02771405Written as daclatasvir
- Study of DAA Treatment for Children and Adolescents With Active HCV Infection in CambodiaActive, not recruitingNot applicableANRS, Emerging Infectious DiseasesNCT05992077Written as Sofosbuvir/Daclatasvir
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19CompletedPhase 2Shin Poong Pharmaceutical Co. Ltd.NCT04532931Written as Sofosbuvir/daclatasvir
- An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver DiseaseCompletedPhase 2Janssen Research & Development, LLCNCT02262728Written as Daclatasvir
- Antiviral Agents Against COVID-19 InfectionCompletedPhase 2/3Hospital do CoracaoNCT04468087Written as Daclatasvir 60 mg
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedPhase 4Tanta UniversityNCT02992457Written as Daclatasvir
- Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVTerminatedPhase 3Bristol-Myers SquibbNCT01866930Written as Daclatasvir (DCV)
- Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) CirrhoticsCompletedPhase 3Tehran University of Medical SciencesNCT02596880Written as Daclatasvir
- Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C VirusStatus unknownPhase 2/3Ain Shams UniversityNCT03540212Written as Daclatasvir and sofosbuvir
- Effect of New Oral Treatment for Hepatitis C Virus on Seminal ParametersCompletedPhase 2/3Benha UniversityNCT05616598Written as Sofosbuvir +daclatasvir+ simeprevir+Ribavirin
- Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients SeraStatus unknownEarly Phase 1Assiut UniversityNCT03882307Written as sofosbuvir and daclatasvir
- COVID-19 Prophylaxis South Africa (COVER HCW)CompletedPhase 2University of Witwatersrand, South AfricaNCT04561063Written as Sofosbuvir/Daclatasvir
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)CompletedPhase 2/3Humanity and Health Research CentreNCT02555943Written as Sofosbuvir and Daclatasvir
- Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) InfectionTerminatedPhase 2Bristol-Myers SquibbNCT03487848Written as Daclatasvir
- A Drug-drug Interaction Study Between Daclatasvir and MetforminCompletedPhase 1Radboud University Medical CenterNCT02565862Written as Daclatasvir
- A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/CobicistatCompletedPhase 1Radboud University Medical CenterNCT02565888Written as Daclatasvir
- A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1CompletedPhase 3Bristol-Myers SquibbNCT02170727Written as DCV/ASV/BMS-791325
- Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude DualCompletedPhase 3Bristol-Myers SquibbNCT01995266Written as Daclatasvir
- Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)CompletedPhase 2Bristol-Myers SquibbNCT02175966Written as DCV/ASV/BMS-791325
See all 92 studies that test daclatasvir →
Given in every arm · 18 — daclatasvir is usual care beside what is tested
- Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral DrugsCompletedPhase 1ViriomNCT03706898Written as Daclatasvir
- Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]CompletedPhase 2/3Johns Hopkins Bloomberg School of Public HealthNCT03480932Written as Daclatasvir
- Safety of Sofosbuvir in People With Advanced Kidney FailureCompletedPhase 3Sanjay Gandhi Postgraduate Institute of Medical SciencesNCT03883698Written as Daclatasvir 60 mg
- Sofosbuvir in Treatment of COVID 19Status unknownPhase 2/3Tanta UniversityNCT04460443Written as Daclatasvir
- Sofosbuvir Containing Regimens in Treatment of COVID 19 PatientsStatus unknownPhase 2/3Tanta UniversityNCT04497649Written as Daclatasvir
- A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver TransplantationCompletedPhase 2Janssen R&D IrelandNCT01938625Written as Daclatasvir
- Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir CombinationCompletedPhase 2/3Ain Shams UniversityNCT03490097Written as sofosbuvir plus daclatasvir
- Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available MedicationsCompletedPhase 2Bristol-Myers SquibbNCT01455090Written as BMS-790052
- Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C VirusCompletedPhase 2Bristol-Myers SquibbNCT01628692Written as Daclatasvir
- Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsCompletedPhase 2Bristol-Myers SquibbNCT01428063Written as Daclatasvir
- A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3WithdrawnPhase 2Bristol-Myers SquibbNCT02551861Written as Daclatasvir
- Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of CareCompletedPhase 2Bristol-Myers SquibbNCT01359644Written as Daclatasvir
- Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of CareCompletedPhase 2Bristol-Myers SquibbNCT01012895Written as BMS-790052
- UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated CirrhosisCompletedPhase 3Bristol-Myers SquibbNCT01973049Written as Daclatasvir
- Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)CompletedPhase 3Bristol-Myers SquibbNCT01581203Written as Daclatasvir (DCV)
- Study of Drug Combination on Pharmacokinetics in Healthy VolunteersCompletedPhase 1Bristol-Myers SquibbNCT02175602Written as DCV 3DAA FDC
- Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02045966Written as DCV 3DAA FDC
- Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis CWithdrawnPhase 2Bristol-Myers SquibbNCT01629732Written as Daclatasvir
As the comparator · 3 — what is tested is compared with daclatasvir
- A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 InfectionCompletedPhase 3AbbVieNCT02640157Written as Daclatasvir
- A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV InfectionCompletedPhase 3Egyptian Liver HospitalNCT03186313Written as Sofosbuvir + Daclatasvir + Ribavirin
- UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis CCompletedPhase 3Bristol-Myers SquibbNCT02123654Written as Daclatasvir
Codes
What other systems call daclatasvir · ClinicalTrials.gg INT005615
- MeSH (NLM) C549273daclatasvirConfirmed NLM, Wikidata
- UNII (FDA) LI2427F9CIDACLATASVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1606218Confirmed FDA, Wikidata
- Wikidata Q5207712daclatasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114981DaclatasvirOne source FDA
- DrugBank DB09102One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C549273 | daclatasvir | Confirmed NLM, Wikidata |
| UNII (FDA) | LI2427F9CI | DACLATASVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1606218 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5207712 | daclatasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114981 | Daclatasvir | One source FDA |
| DrugBank | DB09102 | — | One source Wikidata |
Also registered as daclatasvir hydrochloride (UNII 50ZO25C11D · RxNorm 1606217).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.